The effect of P-glycoprotein on methadone hydrochloride flux in equine intestinal mucosa.

Methadone is an effective analgesic opioid that may have a place for the treatment of pain in horses. However, its absorption seems to be impaired by the presence of a transmembrane protein, P-glycoprotein, present in different tissues including the small intestine in other species. This study aims to determine the effect of the P-glycoprotein on methadone flux in the equine intestinal mucosa, as an indicator of in vivo drug absorption. Jejunum tissues from five horses were placed into the Ussing chambers and exposed to methadone solution in the presence or absence of Rhodamine 123 or verapamil. Electrical measurements demonstrated tissue viability for 120 min, and the flux of methadone across the jejunal membrane (mucosal to submucosal direction) was calculated based on the relative drug concentration measured by ELISA. The flux of methadone was significantly higher only in the presence of verapamil. P-glycoprotein was immunolocalized in the apical membrane of the jejunal epithelial cells (enterocytes), mainly located in the tip of the villi compared to cells of the crypts. P-glycoprotein is present in the equine jejunum and may possibly mediate the intestinal transport of methadone. This study suggests that P-glycoprotein may play a role in the poor intestinal absorption of methadone in vivo.

Influência do treinamento aeróbio sobre o cortisol e glicose plasmáticos em equinos / Influence of the aerobic training on cortisol and glucose levels in horses

Estudou-se a resposta do cortisol e da glicemia em 12 equinos da raça Puro Sangue Árabe destreinados (T0) por oito meses e submetidos a um período de 90 dias de treinamento aeróbio (T90). Para avaliação dos efeitos do treinamento, empregou-se teste ergométrico constituído de exercício progressivo em esteira rolante, acompanhado por colheitas de sangue 15 segundos antes do término de cada etapa de esforço. A velocidade (intensidade) do treino foi definida como sendo 80 por cento da V4 (velocidade na qual a lactacidemia atinge 4mmol/L). Adicionalmente, no último mês de treinamento, foi instituído, uma vez por semana, exercício com velocidades variáveis, chamado "fartlek". Após 90 dias de treinamento, a concentração plasmática de cortisol elevou-se e após o teste de esforço (20min), houve aumento da glicemia. Este resultado reflete a possibilidade de adaptação ao treinamento. Conclui-se que o cortisol plasmático pode ser utilizado como ferramenta na avaliação de um programa de treinamento em equinos.

Cortisol and glucose responses were evaluated in 12 Arabian (PSA) horses submitted to a detraining period of eight months (T0) and to 90 days of aerobic training (T90). For the evaluation of the effect of training, a standardized incremental exercise test in a treadmill was used. Fifteen seconds before the ending of each effort step, blood samples were collected. The speed (intensity) of the training was defined as being 80 percent of the V4 (speed at which the blood lactate concentration reaches 4mmol/L). Additionally, in the last month of training, velocity play, a type of exercise with varying velocities called "fartlek" was instituted, once a week. Results showed that after 90 days of training, the plasmatic concentrations of cortisol and glucose increased when compared to the untrained horses. This result reflects the possibility of adaptation to the training. The blood cortisol levels may be used as a tool for the evaluation of a training program in horses.

Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses.

Methadone hydrochloride is a synthetic mu-opioid receptor agonist with potent analgesic properties. Oral methadone has been successfully used in human medicine and may overcome some limitations of other analgesics in equine species for producing analgesia with minimal adverse effects. However, there are no studies describing the pharmacokinetics (PK) of oral opioids in horses. The aim of this study was to describe the PK of orally administered methadone (0.1, 0.2 and 0.4 mg/kg) and physical effects in 12 healthy adult horses. Serum methadone concentrations were measured by gas chromatography/mass spectrometry at predetermined time points for 24 h, and PK parameters were estimated using a noncompartmental model. Physical effects were observed and recorded by experienced clinicians. No drug toxicity, behavioural or adverse effects were observed in the horses. The disposition of methadone followed first order elimination and a biphasic serum profile with rapid absorption and elimination phases. The PK profile of methadone was characterized by high clearance (Cl/F), small volume of distribution (V(d)/F) and short elimination half-life (t(1/2)). The mean of the estimated t(1/2) (SD) for each dose (0.1, 0.2 and 0.4 mg/kg) was 2.2 (35.6), 1.3 (46.1) and 1.5 (40.8), and the mean for the estimated C(max) (SD) was 33.9 (6.7), 127.9 (36.0) and 193.5 (65.8) respectively.

Cardiovascular assessment in horses sedated with xylazine or amitraz / Avaliação cardiovascular em eqüinos sedados com xilazina ou amitraz

Cardiovascular effects due to intravenous (IV) xylazine (1.0mg/kg) or amitraz (0.1 or 0.4mg/kg) were evaluated in horses. Left ventricular function indexes, heart rate (HR), and cardiac output (CO) were measured by echocardiography. Second degree atrioventricular (AV) block was detected by electrocardiography. Invasive arterial blood pressure (AP) was also evaluated. All parameters were measured immediately before and during 60 minutes after drug injection. HR, CO, and second degree AV block were different between xylazine and amitraz-0.4mg/kg groups. Xylazine induced initial hypertension 10 minutes after injection, and hypotension was observed 30 minutes after amitraz-0.4mg/kg administration. Except for the second degree AV block which occurred only at five minutes, there was no change in the echocardiographic measurements after administration of amitraz-0.1mg/kg. Thus, amitraz-0.4mg/kg and xylazine (1.0mg/kg) induced similar cardiovascular side effects, but long-lasting action of amitraz-0.4mg/kg in the cardiovascular system was observed.

Avaliaram-se efeitos cardiovasculares decorrentes da administração intravenosa (IV) de xilazina (1,0mg/kg) ou amitraz (0,1 ou 0,4mg/kg) em cavalos. Os índices ventriculares, a freqüência cardíaca (FC) e o débito cardíaco (DC) foram mensurados por ecocardiografia, e o bloqueio atrioventricular de segundo grau (BAV2), detectado por eletrocardiografia. A pressão arterial invasiva foi também avaliada. Todos os parâmetros foram mensurados imediatamente antes e durante 60 minutos após a administração dos fármacos. Os valores da FC, do DC e do BAV2 apresentaram alterações significativas nos grupos da xilazina e do amitraz na dose de 0,4mg/kg. A xilazina induziu hipertensão inicial 10 minutos após sua administração e a dose de 0,4mg/kg amitraz induziu hipotensão após 30 minutos. Exceto pela ocorrência de BAV2 aos cinco minutos, não houve alteração nas mensurações ecocardiográficas após a administração de amitraz-0.1mg/kg. Nas doses utilizadas, a xilazina (1,0mg/kg) e o amitraz-0,4mg/kg promoveram alterações semelhantes no sistema cardiovascular, porém os efeitos cardiovasculares provocados pelo amitraz foram mais prolongados.